NeuroTherapia, Inc.

NeuroTherapia, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for neuroinflammatory disorders, particularly Alzheimer's disease. Their lead product, NTRX-07, is an oral, small molecule drug that targets the CB2 receptor on microglia, specialized cells in the brain that play a key role in the immune system. NTRX-07 works by reducing inflammation and promoting neuronal survival, potentially slowing the progression of neurodegenerative diseases. NeuroTherapia believes this approach offers a promising new path for treating Alzheimer's and other neurological diseases.

The company has successfully completed Phase 1 clinical trials, demonstrating the safety and efficacy of NTRX-07 at specific dosages. NeuroTherapia is now entering Phase 2a clinical trials, focused on further evaluating the clinical activity of NTRX-07 in patients with Alzheimer's disease. The company has received significant funding from investors including Cleveland Clinic Innovations, Brain Trust Accelerator Fund II, Dolby Family Ventures, and the Alzheimer's Drug Discovery Foundation, supporting their ongoing research and development efforts.

NeuroTherapia is a clinical-stage biotechnology company focused on developing oral, small-molecule drugs to address neuroinflammatory conditions of the central nervous system (CNS), including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and other CNS conditions. Their mission is to change the course of these debilitating and deadly CNS diseases by developing therapies that inhibit microglia cells, which are known to express proteins that drive inflammation in the CNS, without affecting the clearance of toxic beta amyloid. They believe their approach will result in improved neuronal function and survival.

NeuroTherapia fosters a collaborative and innovative culture, driven by a shared passion for developing life-changing therapies. They value scientific excellence, teamwork, and a commitment to improving the lives of patients with neurodegenerative diseases. The company encourages open communication, creative problem-solving, and a strong focus on clinical development, reflecting a dynamic and driven environment.